{"unnormalised": "AIIMS Delhi announced a new clinical trial for a novel cancer treatment, specifically targeting stage 3 lung cancer patients. Dr. Rajiv Sharma, the lead oncologist, stated that the trial will involve approximately 50 patients and will run for 12 months, starting 01/11/2024. The treatment, tentatively named 'CureOnco', combines chemotherapy with a new immunotherapy drug.", "normalised": "A-I-I-M-S Delhi announced a new clinical trial for a novel cancer treatment, specifically targeting stage three lung cancer patients. Doctor Rajiv Sharma, the lead oncologist, stated that the trial will involve approximately fifty patients and will run for twelve months, starting first november two thousand and twenty four. The treatment, tentatively named 'CureOnco', combines chemotherapy with a new immunotherapy drug."}
{"unnormalised": "According to reports, CureOnco has shown promising results in preclinical studies, with a 60% reduction in tumor size in mice. The trial aims to assess the safety and efficacy of CureOnco in humans. Patients aged between 18-70 yrs with confirmed stage 3 lung cancer are eligible to participate. Those interested can contact the AIIMS oncology department at 011-26588500.", "normalised": "According to reports, CureOnco has shown promising results in preclinical studies, with a sixty percent reduction in tumor size in mice. The trial aims to assess the safety and efficacy of CureOnco in humans. Patients aged between eighteen to seventy years with confirmed stage three lung cancer are eligible to participate. Those interested can contact the A-I-I-M-S oncology department at zero eleven two six five double eight five hundred."}
{"unnormalised": "\"We're really hopeful about this,\" shared Dr. Sharma in a press briefing held yesterday. \"Lung cancer is a big problem in India, especially in cities like Delhi with high pollution levels. A new treatment option is desperately needed. We aim to publish the initial findings in the Lancet Oncology journal by Q3 2025.”", "normalised": "\"We're really hopeful about this,\" shared Doctor Sharma in a press briefing held yesterday. \"Lung cancer is a big problem in India, especially in cities like Delhi with high pollution levels. A new treatment option is desperately needed. We aim to publish the initial findings in the Lancet Oncology journal by Q three two thousand and twenty five.”"}
{"unnormalised": "The trial also includes a focus on quality of life assessments. Patients will undergo regular check-ups, including CT scans and blood tests, throughout the 12-month period. Any side effects will be closely monitored and managed. The study protocol has been approved by the AIIMS ethics committee.", "normalised": "The trial also includes a focus on quality of life assessments. Patients will undergo regular check-ups, including C-T scans and blood tests, throughout the twelve-month period. Any side effects will be closely monitored and managed. The study protocol has been approved by the A-I-I-M-S ethics committee."}
{"unnormalised": "This trial represents a significant step forward in cancer research in India. AIIMS Delhi is committed to providing cutting-edge treatment options to its patients and hopes that CureOnco will offer a new ray of hope for individuals battling lung cancer. They are also looking for volunteers, compensation ₹1000/day, if interested can register on aiims.edu/clinicaltrials.", "normalised": "This trial represents a significant step forward in cancer research in India. A-I-I-M-S Delhi is committed to providing cutting-edge treatment options to its patients and hopes that CureOnco will offer a new ray of hope for individuals battling lung cancer. They are also looking for volunteers, compensation rupee one thousand per day, if interested can register on aiims dot edu slash clinicaltrials."}
